Recombinant Anti-LDL Receptor antibody [EP1553Y] (ab52818)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP1553Y] to LDL Receptor
- Suitable for: IHC-P, WB
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-LDL Receptor antibody [EP1553Y]
See all LDL Receptor primary antibodies -
Description
Rabbit monoclonal [EP1553Y] to LDL Receptor -
Host species
Rabbit -
Specificity
Some optimisation may be required for detection of the target protein due to low levels of endogenous expression in some samples. Please see images below for suitable positive controls.
-
Tested applications
Suitable for: IHC-P, WBmore details
Unsuitable for: Flow Cyt or ICC/IF -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Synthetic peptide within Human LDL Receptor aa 800 to the C-terminus (C terminal). The exact sequence is proprietary.
Database link: P01130 -
Positive control
- WB: HeLa and RAW264.7 cell lysate. HepG2 whole cell lysate. Mouse liver, lung and colon lysate. Human liver and plasma lysate. IHC-P: Human hepatocellular carcinoma and liver tissue.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.1% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EP1553Y -
Isotype
IgG -
Research areas
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipid metabolism
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Cholesterol Metabolism
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab52818 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P | (2) |
1/500. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
WB | (7) |
1/500 - 1/1000. Detects a band of approximately 100 kDa (predicted molecular weight: 95 kDa).
|
Notes |
---|
IHC-P
1/500. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
WB
1/500 - 1/1000. Detects a band of approximately 100 kDa (predicted molecular weight: 95 kDa). |
Target
-
Function
Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. In case of HIV-1 infection, functions as a receptor for extracellular Tat in neurons, mediating its internalization in uninfected cells. -
Involvement in disease
Defects in LDLR are the cause of familial hypercholesterolemia (FH) [MIM:143890]; a common autosomal semi-dominant disease that affects about 1 in 500 individuals. The receptor defect impairs the catabolism of LDL, and the resultant elevation in plasma LDL-cholesterol promotes deposition of cholesterol in the skin (xanthelasma), tendons (xanthomas), and coronary arteries (atherosclerosis). -
Sequence similarities
Belongs to the LDLR family.
Contains 3 EGF-like domains.
Contains 7 LDL-receptor class A domains.
Contains 6 LDL-receptor class B repeats. -
Post-translational
modificationsN- and O-glycosylated.
Ubiquitinated by MYLIP leading to degradation. -
Cellular localization
Cell membrane. Endomembrane system. Membrane > clathrin-coated pit. Found distributed from the plasma membrane to intracellular compartments. - Information by UniProt
-
Database links
- Entrez Gene: 3949 Human
- Entrez Gene: 16835 Mouse
- Omim: 606945 Human
- SwissProt: P01130 Human
- SwissProt: P35951 Mouse
- Unigene: 213289 Human
- Unigene: 728190 Human
- Unigene: 3213 Mouse
-
Alternative names
- FH antibody
- FHC antibody
- LDL R antibody
see all
Images
-
All lanes : Anti-LDL Receptor antibody [EP1553Y] (ab52818) at 1/1000 dilution
Lane 1 : PC-3 (Human prostate adenocarcinoma epithelial cell) whole cell lysate
Lane 2 : LNCaP (Human prostate carcinoma epithelial cell) whole cell lysate
Lane 3 : Huh7 (Human hepatocellular carcinoma epithelial cell) whole cell lysate
Lane 4 : HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate
Lane 5 : HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate
Lane 6 : A431 (Human epidermoid carcinoma epithelial cell) whole cell lysate
Lane 7 : HEK-293 (Human embryonic kidney epithelial cell) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/20000 dilution
Predicted band size: 95 kDa
Observed band size: 150 kDa why is the actual band size different from the predicted?Blocking buffer: 5% NFDM/TBST
Diluting buffer: 5% NFDM/TBST
-
All lanes : Anti-LDL Receptor antibody [EP1553Y] (ab52818) at 1/1000 dilution
Lane 1 : HeLa (Human epithelial cell line from cervix adenocarcinoma) cell lysate
Lane 2 : HeLa treated with GW3965 for 8 hours at the final concentration of 5uM whole cell lysates
Lane 3 : HeLa treated with GW3965 for 24 hours at the final concentration of 5uM whole cell lysates
Lane 4 : Raw264.7 (Mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysates
Lane 5 : Raw264.7 treated with GW3965 for 8 hours at the final concentration of 5uM whole cell lysates
Lane 6 : Raw264.7 treated with GW3965 for 24 hours at the final concentration of 5uM whole cell lysates
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution (HRP goat anti-rabbit IgG (H+L))
Predicted band size: 95 kDa
Observed band size: 140 kDa why is the actual band size different from the predicted?
Exposure time: 1 minuteBlocking buffer: 5% NFDM/TBST
Diltuion buffer: 5% NFDM/TBST
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LDL Receptor antibody [EP1553Y] (ab52818)
Immunohistochemical analysis of paraffin-embedded human liver sections labeling LDL Receptor with purified ab52818 at dilution of 1:500. The secondary antibody used was ab97051; a goat anti-rabbit IgG H&L (HRP) at dilution of 1/500. The sample was counterstained with hematoxylin. Antigen retrieval was performed using EDTA Buffer; pH 9.0. PBS was used instead of the primary antibody as the negative control and is shown in the inset.
-
Anti-LDL Receptor antibody [EP1553Y] (ab52818) at 0.4 µg/ml + HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg
Secondary
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 95 kDa
Exposure time: 3 minutesBlocking and diluting buffer: 5% NFDM/TBST.
The molecular weight observed is consistent with the literature (PMID: 15199428, PMID: 8349823, PMID: 10906332, PMID: 24918045). -
All lanes : Anti-LDL Receptor antibody [EP1553Y] (ab52818) at 1/1000 dilution
Lane 1 : Mouse liver lysate
Lane 2 : Mouse lung lysate
Lane 3 : Mouse colon lysate
Lane 4 : Human liver lysate
Lane 5 : HepG2 (Human liver hepatocellular carcinoma cell line) cell lysate
Lane 6 : HeLa (Human epithelial cell line from cervix adenocarcinoma) cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/1000 dilution (HRP goat anti-rabbit IgG (H+L))
Predicted band size: 95 kDa
Observed band size: 140 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutesBlocking buffer: 5% NFDM/TBST
Diltuion buffer: 5% NFDM/TBST
-
Anti-LDL Receptor antibody [EP1553Y] (ab52818) at 1/5000 dilution + Mouse liver at 15 µg
Secondary
Goat Anti-Rabbit IgG H&L (HRP) (ab97051)
Predicted band size: 95 kDa
Observed band size: 140 kDa why is the actual band size different from the predicted?
Blocking/Diluting buffer 5% NFDM/TBST -
Anti-LDL Receptor antibody [EP1553Y] (ab52818) at 1/500 dilution + Human plasma total protein lysate at 10 µg
Secondary
Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 95 kDa
Observed band size: 100 kDa why is the actual band size different from the predicted?
Additional bands at: 27 kDa, 48 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 4 minutes
LDL Receptor contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted. -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LDL Receptor antibody [EP1553Y] (ab52818)
Immunohistochemical analysis of paraffin-embedded human hepatocellular carcinoma tissue labeling LDL Receptor with ab52818 at 1/100 dilution followed by goat anti-rabbit IgG H&L (HRP) (ab97051, 1/500). The sample was counterstained with hematoxylin.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (100)
ab52818 has been referenced in 100 publications.
- Wang S et al. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Res 31:126-140 (2021). PubMed: 33420426
- Li Z et al. Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model. Theranostics 11:2953-2965 (2021). PubMed: 33456582
- Emmer BT et al. Genome-scale CRISPR screening for modifiers of cellular LDL uptake. PLoS Genet 17:e1009285 (2021). PubMed: 33513160
- Xu M et al. Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. EBioMedicine 65:103250 (2021). PubMed: 33647772
- Lizardo K et al. Fat tissue regulates the pathogenesis and severity of cardiomyopathy in murine chagas disease. PLoS Negl Trop Dis 15:e0008964 (2021). PubMed: 33826636